Engineering cellular biology, minus the actual cell, is a growing area of interest in biotechnology and synthetic biology. It’s known as cell-free protein synthesis, or CFPS, and it has potential to provide sustainable ways to make chemicals, medicines and biomaterials.
Unfortunately, a long-standing gap in cell-free systems is the ability to manufacture glycosylated proteins – proteins with a carbohydrate attachment. Glycosylation is crucial for a wide range of important biological processes, and the ability to understand and control this mechanism is vital for disease treatment and prevention.
Matthew DeLisa, the William L. Lewis Professor of Engineering in the Smith School of Chemical and Biomolecular Engineering, and Michael Jewett, associate professor of chemical and biological engineering at Northwestern University, have teamed up on a novel approach that bridges this gap. Their system, the first of its kind, capitalizes on the recent advances in CFPS while adding the crucial glycosylation component in a simplified, “one-pot” reaction. In the future, their cell-free glycoprotein synthesis system could be freeze-dried and reactivated for point-of-use protein synthesis by simply adding water.
DeLisa and Jewett are co-senior authors of “Single-pot Glycoprotein Biosynthesis Using a Cell-Free Transcription-Translation System Enriched with Glycosylation Machinery,” published July 12 in Nature Communications.
Thapakorn Jaroentomeechai, Ph.D. student in the DeLisa Research Group, and Jessica Stark ’12, Ph.D. student in the Jewett group, are co-first authors.
“If you really want to have a useful, portable and deployable vaccine or therapeutic protein technology that’s cell free, you have to figure out the carbohydrate attachment,” DeLisa said. “That’s, in essence, what we’ve done in a very powerful way.”
This work could impact development of decentralized manufacturing strategies. Rapid access to protein-based medicines in remote settings could change lives; new biomanufacturing paradigms suitable for use in low-resource settings might promote better access to costly drugs through local, small-batch production.
DeLisa has done a great deal of research on the molecular mechanisms underlying protein biogenesis in the complex environment of a living cell, such as Escherichia coli (E. coli). While his lab has made some notable breakthroughs, the limitations of this area, he said, are the cell walls themselves.
Jewett’s lab at Northwestern has invested much of its research efforts into cell-free synthetic biology, which leverages nature’s most elegant biomachinery outside the confines of the cell, so a collaboration was a natural extension of both labs’ work.
“In bacterial cell engineering, you’re constantly in a tug of war,” Jewett said. “You’re introducing a mechanism or capability that’s of interest to you as a scientist, but what the cell is trying to do for itself is grow and survive.”
For their new method, the team prepared cell extracts from an optimized laboratory strain of E. coli, CLM24, that were selectively enriched with key glycosylation components. The resulting extracts enabled a simplified reaction scheme, which the team has dubbed cell-free glycoprotein synthesis (CFGpS).
“A major advance of this work is that our cell-free extracts contain all of the molecular machinery for protein synthesis and protein glycosylation,” Stark said. “What that means is you only need to add DNA instructions for your protein of interest to make a glycoprotein in CFGpS. This is a drastic simplification from cell-based methods and allows us to make sophisticated glycoprotein molecules in less than a day.”
And the CFGpS method is highly modular, allowing for the use of distinct and diverse extracts to be mixed for the production of a variety of glycoproteins.
“Because we chose E. coli, which lacks its own glycosylation machinery, to build our CFGpS platform, it gave us a blank slate for bottom-up engineering of any desired glycosylation system,” Jaroentomeechai said. “This gives us the unique ability to control carbohydrate structures and purities of the glycoproteins at levels that are not currently achievable in other cell-based expression systems.”
Even in developed countries like the U.S., the move toward personalized medicine makes this type of on-demand drug production protocol attractive. “You could use a test tube instead of a 50,000-liter bioreactor to make your product, which opens the door to a personalized biomanufacturing paradigm where each patient can receive a unique protein medicine tailored to their physiology,” he said.
The Latest on: Personalized biomanufacturing
via Google News
The Latest on: Personalized biomanufacturing
- U.S. pharmaceutical giants cozy up to B.C. biotechson January 16, 2022 at 8:12 am
Since then, other American medical giants have taken an increased liking to the West Coast biotech scene, boosting the potential to raise the profile of made-in-B.C. innovations. “This has opened a ...
- Absci and deep learning's quest for the perfect proteinon January 7, 2022 at 10:56 am
The company has used one giant A.I. representation of proteins to broaden the search for novel biologics and hopes to do everything in silico someday.
- Services to Accelerate Genome Editing Researchon December 21, 2021 at 4:00 pm
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products. A powerful technology, widely used in genome science, ...
- Private Label & Custom Manufactured Microplateson December 21, 2021 at 1:57 pm
Drawing upon its expertise in polymer moulding, surface treatment, specialist assembly and knowledge of analytical, healthcare and life science applications has enabled Porvair Sciences to become a ...
- People to Meet in 2022: Luis Pedrajaon December 20, 2021 at 3:01 am
The 10-week program supported roughly a dozen non-native English speakers who underwent training in basic wrap-around soft skills before learning about biomanufacturing content and industry ...
- People to Meet in 2022: Matt Zicaroon December 20, 2021 at 3:01 am
In the city proper, this is happening through The Reactory biomanufacturing campus, whose first occupant will be a $60-million facility belonging to Chinese biomanufacturer WuXi Biologics.
- Cancer Research & Oncology 2018on December 18, 2021 at 1:17 pm
Each year we see progress in immunotherapy, treatments involving nanotechnology, advances in targeted and personalized therapeutics and drug development, and a decrease in mortality rates due to a ...
- Maine forestry, biomanufacturing projects are in the running for $100M grant prizeson December 14, 2021 at 4:00 pm
Their multi-state coalition to support biomanufacturing infrastructure will prime New England’s commitment to innovation and science, helping to ensure a brighter future for generations to come.” ...
- Restored $750K Medford Home Expected To Sell Faston December 13, 2021 at 5:23 am
Unique touches include a custom barn door, designer lighting and an arbor entry to the yard. It's expected to sell faster than 99 percent of nearby homes, according to Redfin. Click here for more ...
via Bing News